The FDA approves Aduhelm for the treatment of early Alzheimer's disease. Aduhelm targets brain plaque formation to slow the rate of cognitive decline.

If all goes well, thanks to artificial intelligence, we may soon have a new AI-synthesized drug capable of assisting OCD patients in managing their symptoms and thus leading normal lives.

Readers, including even experts, are falling for a hard sell job by venture capitalists who launder their funding of the study through a nonprofit foundation and seek not legalization

Evidence that the newspaper is not sufficiently detached from promoters to provide an open-minded but skeptical perspective that readers should be able to expect.